🎤Dr. Leigh Terry (University of Alabama)In this episode of Concentrating on Chromatography, we sit down with Dr. Leigh Terry from the University of Alabama to explore one of the biggest challenges in environmental analysis today: understanding—and accurately measuring—PFAS in water systems.While most regulatory methods focus on a small number of compounds like PFOA and PFOS, there may be thousands of PFAS compounds in the environment—and much of that burden goes undetected.<h4>In this episode, we cover:</h4><ul><li>Why PFAS are called “forever chemicals” (and why that label is evolving)</li><li>The limitations of targeted LC-MS/MS methods</li><li>What the fluorine mass balance problem reveals about PFAS destruction</li><li>How combustion ion chromatography (CIC) helps measure total organofluorine</li><li>Why “99.99% removal” doesn’t always mean what you think</li><li>Where PFAS actually end up in wastewater treatment systems</li><li>The most effective technologies for PFAS removal today</li><li>Why drinking water may only account for ~20% of total PFAS exposure</li></ul><h4>Key Insight:</h4>Even when analyzing dozens of PFAS compounds, researchers may only be capturing a small fraction of total organic fluorine—raising major questions about how we monitor and regulate these contaminants.<h3>Video Transcription</h3>In this episode of Concentrating on Chromatography, Dr. Leigh Terry discusses PFAS contamination in drinking water, the analytical challenges associated with measuring these compounds, current treatment technologies, and future directions for monitoring and regulation. The conversation highlights how analytical chemistry, environmental engineering, and public health intersect in addressing one of today's most discussed classes of emerging contaminants.<h4>Understanding PFAS and Their Significance</h4><h5>The University of Alabama Water Quality Research Center</h5>Dr. Leigh Terry is part of the University of Alabama's Center for Water Quality Research. The center operates an analytical laboratory focused on drinking water quality and the detection of contaminants at extremely low concentrations.The laboratory specializes in:<ul><li>Drinking water analysis</li><li>Organic contaminants</li><li>Emerging contaminants</li><li>PFAS monitoring</li><li>Water quality research</li></ul>Their work supports both research initiatives and practical solutions for water utilities and environmental agencies.<h4>Why Focus on PFAS?</h4>Although PFAS compounds have existed since the 1940s, public awareness has increased dramatically only in recent years.According to Dr. Terry, several factors contributed to the rapid growth of PFAS research:<ul><li>Increased media attention</li><li>New regulatory initiatives</li><li>Growing evidence of human exposure</li><li>Expanding research opportunities</li><li>Greater understanding of potential health risks</li></ul>PFAS are not new contaminants. Rather, society is only beginning to understand their prevalence in the environment and their potential impacts on human health.<h4>The Development of Standardized PFAS Methods</h4>One major advancement in PFAS analysis has been the development of standardized EPA methods.These methods allow:<ul><li>Consistent testing procedures</li><li>Comparable results between laboratories</li><li>Regulatory monitoring</li><li>Reliable data interpretation</li></ul>Dr. Terry notes that many of these standardized approaches began appearing around 2018–2019, providing a common framework for analytical laboratories and researchers.<h4>How Large Is the PFAS Universe?</h4>Many people are familiar with PFOA and PFOS, two of the most heavily studied PFAS compounds. However, these represent only a small fraction of the broader PFAS family.PFOA and PFOS are often referred to as:<ul><li>Legacy PFAS compounds</li><li>Original PFAS contaminants</li><li>Early commercial PFAS chemicals</li></ul>The challenge is that even minor modifications to molecular structure create entirely new PFAS compounds.Researchers estimate:<ul><li>Thousands of PFAS compounds exist</li><li>Some estimates exceed 10,000 compounds</li><li>Exact numbers depend on how PFAS are defined</li></ul>Scientific debate continues regarding classification and definition, making precise counting difficult.<h4>Why PFAS Are Called "Forever Chemicals"</h4>Dr. Terry notes that the phrase "forever chemicals" has become widely used, although she suggests the terminology could benefit from rebranding.PFAS persistence results from two key chemical properties.<h5>1. Amphiphilic Structure</h5>PFAS molecules contain:<ul><li>A water-loving (hydrophilic) head group</li><li>A water-repelling (hydrophobic) fluorinated tail</li></ul>This unusual combination allows PFAS to partition between:<ul><li>Water</li><li>Solids</li><li>Air-water interfaces</li><li>Foam</li></ul>Unlike many organic compounds, PFAS can interact effectively with multiple environmental phases.<h5>2. Extremely Strong Carbon–Fluorine Bonds</h5>The carbon–fluorine bond is among the strongest bonds in organic chemistry.As Dr. Terry explains:<ul><li>Large amounts of energy are required to break these bonds</li><li>Natural degradation processes are often ineffective</li><li>Destruction can require highly aggressive treatment conditions</li></ul>These properties make PFAS extremely persistent in both environmental systems and biological organisms.<h4>Toxicity, Regulations, and Environmental Behavior</h4><h5>Understanding PFAS Toxicity</h5>One of the biggest challenges in PFAS regulation is the incomplete understanding of toxicity.Dr. Terry explains that EPA regulations generally consider three factors:<ul><li>Presence in drinking water sources</li><li>Toxicity to humans</li><li>Availability of practical treatment options</li></ul>While some PFAS compounds are known to be harmful, many others remain insufficiently studied. Furthermore, PFAS often occur as mixtures rather than individual compounds.This creates important scientific questions:<ul><li>What is the toxicity of individual PFAS?</li><li>What is the toxicity of PFAS mixtures?</li><li>How should cumulative exposure be evaluated?</li></ul>These uncertainties continue to drive active research.<h4>What Happens to PFAS in Wastewater Treatment Plants?</h4>PFAS do not behave like many conventional contaminants.Rather than remaining fully dissolved in water, they often accumulate at interfaces such as:<ul><li>Water-solid interfaces</li><li>Water-air interfaces</li><li>Foam layers</li><li>Biological solids</li></ul>As a result:<ul><li>Some PFAS accumulate in biosolids</li><li>Some partition into foam</li><li>Some remain in treated effluent</li></ul>Their distribution depends on wastewater composition and treatment processes.<h4>Regulatory Monitoring and Targeted LC-MS Analysis</h4>Current EPA regulations focus on targeted analysis of specific PFAS compounds.Examples include:<ul><li>PFOA</li><li>PFOS</li></ul>Drinking water regulations currently establish maximum contaminant levels (MCLs) for these compounds at extremely low concentrations.Advantages of targeted LC-MS analysis include:<ul><li>Clearly defined analytes</li><li>Established regulatory limits</li><li>High analytical sensitivity</li><li>Reliable quantitation</li></ul>However, limitations remain:<ul><li>Only a small subset of PFAS is measured</li><li>Many PFAS compounds remain undetected</li><li>Total PFAS burden may be underestimated</li></ul>As Dr. Terry notes, targeted analysis provides only part of the overall picture.<h4>The Fluorine Mass Balance Problem</h4>One of the most important concepts discussed in the interview is fluorine mass balance.When PFAS degrade, fluorinated fragments may remain in the environment.This creates a critical question:Are treatment technologies truly destroying PFAS, or merely transforming them into shorter-chain PFAS compounds?To answer this, researchers perform fluorine mass balance calculations using:<ul><li>Targeted PFAS analysis</li><li>Fluoride measurements</li><li>Total organic fluorine measurements</li></ul>A successful destruction process should ultimately convert PFAS into fluoride ions rather than simply producing smaller PFAS molecules.<h4>Advanced Analysis, Treatment Technologies, and Future Directions</h4><h5>Combining Targeted and Bulk Fluorine Measurements</h5>Dr. Terry's group complements targeted LC-MS analysis with measurements of total organic fluorine.Approaches include:<ul><li>Absorbable Organic Fluorine (AOF)</li><li>Extractable Organic Fluorine (EOF)</li><li>Combustion Ion Chromatography (CIC)</li></ul>In these methods:<ul><li>Organic fluorine is captured</li><li>Samples are combusted</li><li>Released fluoride is quantified</li></ul>This provides insight into total fluorinated content, although contributions may originate from sources beyond PFAS, including pharmaceuticals and consumer products.<h4>Surprising Findings from Combined Analysis</h4>One important finding from wastewater studies was that targeted PFAS measurements accounted for only a small fraction of total organic fluorine.Dr. Terry reports that:<ul><li>Approximately 4% of measured AOF could be explained by targeted PFAS compounds</li><li>The majority of organic fluorine remained unidentified</li></ul>This suggests that environmental fluorine chemistry is considerably more complex than currently represented by routine monitoring programs.<h4>Preventing PFAS Contamination in the Laboratory</h4>PFAS analysis requires exceptionally strict quality control.Dr. Terry's laboratory routinely:<ul><li>Tests every new batch of SPE cartridges</li><li>Tests carbon tubes before use</li><li>Uses DI water blanks</li><li>Verifies consumables labeled as PFAS-free</li><li>Collects field blanks</li><li>Monitors analytical blanks throughout workflows</li></ul>These practices help prevent contamination from laboratory materials and consumables, a common challenge in ultra-trace PFAS analysis.<h4>Current PFAS Treatment Technologies</h4>Three technologies currently dominate PFAS removal in drinking water treatment:<ul><li>Granular Activated Carbon (GAC)</li><li>Ion Exchange Resins</li><li>Reverse Osmosis (RO)</li></ul>Selection depends on:<ul><li>PFAS concentration</li><li>Water quality</li><li>Local operating conditions</li><li>Utility infrastructure</li></ul>Although many emerging technologies are being investigated, these remain the most widely implemented solutions.<h4>Membrane Filtration and Pretreatment</h4>Dr. Terry collaborates with colleagues studying membrane-based PFAS treatment.Her own work focuses on pretreatment through biological filtration.The strategy involves:<ul><li>Removing natural organic matter</li><li>Reducing membrane fouling</li><li>Improving membrane performance</li><li>Extending operational efficiency</li></ul>This integrated approach demonstrates how multiple treatment technologies can work together to improve PFAS removal.<h4>Regional Monitoring Projects</h4>The University of Alabama team participates in EPA-supported monitoring efforts along the Gulf Coast.Their observations indicate:<ul><li>PFAS rarely occur alone</li><li>Multiple PFAS compounds frequently co-occur</li><li>Contamination often originates from identifiable point sources</li></ul>Examples include:<ul><li>Industrial facilities</li><li>Manufacturing operations</li><li>Military installations</li><li>Carpet manufacturing facilities</li></ul>Source identification remains a critical component of environmental monitoring programs.<h4>Future Directions for PFAS Monitoring</h4>Looking ahead, Dr. Terry sees several opportunities for improvement.Desired advances include:<ul><li>In situ monitoring technologies</li><li>Portable detection systems</li><li>Reduced analytical complexity</li><li>Lower instrument costs</li><li>Less expensive consumables</li><li>Faster analysis workflows</li></ul>Current PFAS testing requires substantial expertise, specialized instrumentation, and rigorous quality control, making widespread implementation challenging.<h4>Dr. Terry's Perspective on Long-Term Solutions</h4>When asked what major PFAS challenge she would most like to solve, Dr. Terry offered a broader perspective.Rather than focusing solely on remediation, she emphasized prevention.Her view is that society should:<ul><li>Better evaluate chemical toxicity before commercialization</li><li>Assess risks before large-scale deployment</li><li>Reduce introduction of harmful compounds into the environment</li><li>Support utilities tasked with contaminant removal</li></ul>She notes that water utilities often bear the responsibility of removing contaminants they did not create, highlighting the need for broader societal and regulatory support.<h4>Final Thoughts</h4>Dr. Terry encourages consumers to:<ul><li>Learn where their drinking water originates</li><li>Read annual water quality reports</li><li>Stay informed about local water quality</li><li>Consider appropriate home filtration where needed</li></ul>At the same time, she emphasizes confidence in municipal water systems and the importance of continued investment in water quality research, monitoring, and treatment technologies.<h4>Conclusion</h4>PFAS remain one of the most complex challenges in environmental chemistry and water treatment. Through advanced analytical methods such as LC-MS/MS, combustion ion chromatography, fluorine mass balance approaches, and large-scale monitoring programs, researchers like Dr. Leigh Terry are helping improve our understanding of these persistent contaminants.The interview highlights that solving the PFAS challenge will require a combination of better analytical tools, improved treatment technologies, stronger regulatory frameworks, and a greater emphasis on prevention before contaminants enter the environment.<blockquote>This text has been automatically transcribed from a video presentation using AI technology. It may contain inaccuracies and is not guaranteed to be 100% correct.</blockquote><blockquote><h4>Concentrating on Chromatography Podcast</h4>Dive into the frontiers of chromatography, mass spectrometry, and sample preparation with host David Oliva. Each episode features candid conversations with leading researchers, industry innovators, and passionate scientists who are shaping the future of analytical chemistry. From decoding PFAS detection challenges to exploring the latest in AI-assisted liquid chromatography, this show uncovers practical workflows, sustainability breakthroughs, and the real-world impact of separation science. Whether you’re a chromatographer, lab professional, or researcher you'll discover inspiring content!You can find Concentrating on Chromatography Podcast in podcast apps:<ul><li><a target="_blank" rel="noopener noreferrer" href="https://open.spotify.com/show/1wZg67rCjoGju4yhqxI3tL">Spotify</a></li><li><a target="_blank" rel="noopener noreferrer" href="https://podcasts.apple.com/tz/podcast/concentrating-on-chromatography/id1788429185">Apple podcast</a></li><li><a target="_blank" rel="noopener noreferrer" href="https://podscan.fm/podcasts/concentrating-on-chromatography">podscan</a></li></ul>and on <a target="_blank" rel="noopener noreferrer" href="https://www.youtube.com/@ChromatographyTalk/videos">YouTube channel</a></blockquote>

PFAS in Water: Why We’re Missing 96% of the Problem

This study evaluates an immobilized enzyme reactor (IMER) containing peptide N-glycosidase from Rudaea cellulosilytica (PNGase Rc) for rapid online deglycosylation of intact glycoproteins. Human glycoproteins and therapeutic antibodies were used as model substrates to assess reactor performance.The PNGase Rc IMER efficiently removed complex sialylated and core-fucosylated glycans, simplifying protein characterization and glycosylation-site analysis. The approach offers a fast and effective solution for bioanalytical workflows, biopharmaceutical quality control, and stability testing of therapeutic proteins.<blockquote><h4>The original article</h4><h4><a target="_blank" rel="noopener noreferrer" href="https://pubs.acs.org/doi/10.1021/acsomega.6c00577">Online Deglycosylation of Monomeric Intact Proteins Using the PNGase Rc Immobilized-Enzyme Reactor</a></h4>Katarína Molnárová, Petr Novák, Jana Nováková, and Petr Pompach*ACS Omega 2026, 11, 17, 25724–25729<a target="_blank" rel="noopener noreferrer" href="https://doi.org/10.1021/acsomega.6c00577">https://doi.org/10.1021/acsomega.6c00577</a><h6>licensed under <a target="_blank" rel="noopener noreferrer" href="https://creativecommons.org/licenses/by/4.0/">CC-BY 4.0</a></h6></blockquote>Selected sections from the article follow. Formats and hyperlinks were adapted from the original.<div>Protein glycosylation, in which monosaccharide units are attached to a protein backbone through enzymatic pathways, is involved in many important biochemical processes and is considered one of the most important post-translational modifications. <a href="javascript:void(0);">(1)</a> It affects not only the stability and secretion of proteins, cell–cell interactions, and receptor–ligand recognition mechanisms but also the biological activity, plasma half-life, immunogenicity, pharmacodynamics, and pharmacokinetics of biotherapeutics. <a href="javascript:void(0);">(2−5)</a> Therapeutical monoclonal antibodies (mAbs) are among the best known pharmaceuticals that are based on glycoproteins. <a href="javascript:void(0);">(6)</a> Over 90% of the mAbs are derived from immunoglobulin G (IgG), in which N-glycosylation occurs at Asn297 of the Fc region and is responsible for modulating immune responses and interactions with other proteins. <a href="javascript:void(0);">(7,8)</a> In cancer treatment, mAbs are used to increase the response of the immune system against the tumor cell, thus inhibiting the cancerous cell growth and helping with the destruction and elimination. <a href="javascript:void(0);">(9)</a> Among the most commonly used mAbs are trastuzumab, bevacizumab, cetuximab, or margetuximab, which are used as an additional treatment for breast, colorectal, prostate, or lung cancer. <a href="javascript:void(0);">(10)</a>Mass spectrometry (MS)-based methods have become a method of choice in the analysis of mAbs that can provide information on sequence, post-translational modifications, and glycosylation profiles. <a href="javascript:void(0);">(11)</a> The enzymatic removal of the attached glycans from the protein backbone can reduce the complexity of the MS analysis, which can lead to a better understanding of the protein structure and modifications. In glycoproteomics, peptide-N-glycosidase F (PNGase F) is most used for glycan removal. It cleaves the linkage between the Asn residue and the N-acetylglucosamine (GlcNAc). <a href="javascript:void(0);">(12)</a> Jmeian et al. developed a monolithic PNGase F enzyme reactor fabricated in fused silica using a glycidyl methacrylate-co-ethylene dimethacrylate polymer and integrated it into an LC–MS workflow. The authors demonstrated the applicability of this system for the characterization of released neutral and acidic N-glycans by LC–MS analysis. <a href="javascript:void(0);">(13)</a> In another study, oriented immobilization of PNGase F onto a methacrylate-based monolithic support via glutathione-S-transferase–glutathione affinity coupling was employed to release N-glycans from denatured ribonuclease B and fetuin, as well as from native IgG. The released glycans and the corresponding deglycosylated proteins were subsequently analyzed by MALDI-MS. <a href="javascript:void(0);">(14)</a>Gramlich et al. showed the potential of PNGase Rc for N-glycan hydrolysis from both tryptic peptides and native glycoproteins at a low pH. The favorable properties of PNGase Rc, including activity at acidic pH and compatibility with reducing agents such as tris(2-carboxyethyl)phosphine hydrochloride (TCEP) and denaturants like urea, make this enzyme well suited for online intact protein deglycosylation workflows. <a href="javascript:void(0);">(15,16)</a>In this report, we demonstrate the potential of the PNGase Rc IMER for rapid online deglycosylation of reduced monomeric glycoproteins, including human haptoglobin (Hp), human transferrin, anti-hHD6, and the therapeutic monoclonal antibodies trastuzumab and bevacizumab. The column retained its activity over more than 150 consecutive measurements, highlighting its robustness, suitability for repeated use in bioanalytical workflows, and applicability to pharmaceutical research and development.<h4>Experimental Section</h4><h5>Instrumentation and Experimental Conditions</h5>Automated sample handling and online deglycosylation were carried out using the HDX workstation (AffiPro, Czech Republic). The scheme of the system is shown on <a target="_blank" rel="noopener noreferrer" href="https://pubs.acs.org/doi/10.1021/acsomega.6c00577#fig1">Figure 1</a>. Samples of 50 mM ammonium bicarbonate buffer (pH 8.2) and 40 mM TCEP were placed in a sample tray at 4 °C. Ten microliters of the protein sample at a concentration of 0.03 mg/mL (0.3 μg per injection) were added to 40 μL of 50 mM ammonium bicarbonate and then transferred to 50 μL of 40 mM TCEP, pH 2.3. The disulfide bond reduction was carried at 40 °C for 5 min. The automated sample handling system injected 100 μL of the reaction mixture into the sample loop and switched the injection valve. Online deglycosylation was performed at room temperature using a PNGase Rc IMER (2.1 × 20 mm, AffiPro, Czech Republic) at a flow rate of 50 μL/min, followed by protein desalting on an OPTI-TRAP (0.5 × 2 mm) trap column (Optimize Technologies Inc., Oregon City, Oregon, USA) heated to 55 °C for 10 min with 0.2% formic acid delivered by an <a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/library?mainauthorItems=10&amp;search=1260+Infinity+III+isocratic+pump">Agilent 1260 Infinity III isocratic pump</a> (Agilent Technologies, Santa Clara, California, USA). By switching the trap valve, the protein was eluted by an acetonitrile gradient [(min)/% B] 0/10-9/10-16/70-16.5/90-17/90-18/10-23/10] delivered by the <a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/library?mainauthorItems=10&amp;search=1290+Infinity+II+LC">Agilent 1290 Infinity II HPLC</a> system (Agilent Technologies, Santa Clara, California, USA) at a flow rate of 20 μL/min. The mobile phase A consisted of 5% acetonitrile with 1% propan-2-ol and 0.1% formic acid, and the mobile phase B consisted of 95% acetonitrile with 1% propan-2-ol and 0.1% formic acid. The <a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/library?mainauthorItems=8&amp;search=maXis+Q-TOF">maXis Q-TOF mass spectrometer</a> (Bruker Daltonics, Bremen, Germany) was operated in the survey MS mode in a mass range of m/z 50–3000. The acquired data were analyzed and processed by DataAnalysis 4.4 (Bruker Daltonics) and deconvoluted by UniDec <a href="javascript:void(0);">(17)</a> with the following parameters: data processing range, m/z 500–3000; charge range, 1–80; allowed mass range, 1,000–80,000; sampling rate, 10 Da; peak detection range, 500 Da; and peak detection threshold, 0.1.<img src="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/ACS_Omega_2026_11_17_25724_25729_Figure_1_Schematic_of_the_automated_sample_handling_system_for_online_protein_deglycosylation_and_desalting_d4ee48b627.jpg" alt="ACS Omega 2026, 11, 17, 25724–25729: Figure 1. Schematic of the automated sample handling system for online protein deglycosylation and desalting. Protein samples, along with 50 mM ammonium bicarbonate and 40 mM TCEP stock solutions were placed in a sample tray chilled to 4 °C, while a second tray heated to 40 °C was used for disulfide bond reduction with TCEP buffer." srcset="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/thumbnail_ACS_Omega_2026_11_17_25724_25729_Figure_1_Schematic_of_the_automated_sample_handling_system_for_online_protein_deglycosylation_and_desalting_d4ee48b627.jpg 245w," sizes="100vw" width="1287" height="386"><h4>Results and Discussion</h4>The performance of the PNGase Rc IMER for the removal of complex N-glycans from intact proteins was tested using heavily glycosylated human Hp with four glycosylation sites (Asn184, Asn207, Asn211, and Asn241) <a href="javascript:void(0);">(18)</a> located at the β-chain and occupied by complex N-glycans terminated with sialic acid. Haptoglobin phenotype 2-1, used in this study, forms multimers consisting of β-chain and disulfide linked α1 and α2 chains. <a href="javascript:void(0);">(19)</a> The detection of glycosylated Hp β-chain requires reduction of the disulfide bonds by incubating the protein with a reducing reagent. TCEP is a common reducing reagent used for fast reduction of disulfide bonds at various pH levels. Forty degrees Celsius, the maximum temperature of the PAL tray, and 5 min of incubation were sufficient for complete reduction of Hp disulfide bonds. Individual signals corresponding to the glycosylated β-chain were observed in the m/z range of 35,800–37,400 (<a target="_blank" rel="noopener noreferrer" href="https://pubs.acs.org/doi/10.1021/acsomega.6c00577#fig2">Figure 2</a>a). The limited resolution of the mass spectrometer did not allow assigning the different glycoforms of the haptoglobin β-chain, which is occupied by biantennary, triantennary, or tetraantennary glycans with various amounts of sialic acid and fucose. <a href="javascript:void(0);">(20,21)</a> The nonglycosylated α1 and α2 chains were observed at m/z 9190 and 15,940. When the PNGase Rc IMER was integrated into the flow system, a signal at m/z 27,270 was detected, demonstrating complete deglycosylation of the haptoglobin β-chain (<a target="_blank" rel="noopener noreferrer" href="https://pubs.acs.org/doi/10.1021/acsomega.6c00577#fig2">Figure 2</a>b).<img src="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/ACS_Omega_2026_11_17_25724_25729_Figure_2_A_Mass_spectrum_of_human_Hp_without_the_PN_Gase_Rc_IMER_implemented_in_the_system_0ecca84ed4.jpg" alt="ACS Omega 2026, 11, 17, 25724–25729: Figure 2. (A) Mass spectrum of human Hp without the PNGase Rc IMER implemented in the system. The base peak signals of the spectrum correspond to both α1 and α2 chains. The signal of the β chain is spread across its different glycoforms. (B) Mass spectrum of human Hp with the PNGase Rc IMER implemented in the system. The signal of the deglycosylated β chain is higher compared to its glycosylated form and observed only at m/z 27,270. This indicates complete removal of glycans from the Hp β chain." srcset="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/thumbnail_ACS_Omega_2026_11_17_25724_25729_Figure_2_A_Mass_spectrum_of_human_Hp_without_the_PN_Gase_Rc_IMER_implemented_in_the_system_0ecca84ed4.jpg 245w," sizes="100vw" width="2015" height="913">In a previous study by Krenkova et al., the PNGase F IMER was used for deglycosylation of IgG, RNase B, and bovine fetuin with follow-up mass spectrometry detection of both released glycans and intact proteins using MALDI-TOF MS. <a href="javascript:void(0);">(14)</a> The authors demonstrated an effective method for rapid protein deglycosylation, which, however, requires additional sample handling prior to mass spectrometry measurement. The other study by Jmeian et al., which focused on released N-glycans, implemented a PNGase F IMER with online LC–MS detection. <a href="javascript:void(0);">(13)</a> The authors show the effectiveness of the method by identifying many different glycans released from a single protein or from a complex plasma mixture. Our approach is not directly intended for released N-glycan analysis; instead, it demonstrates the ability to measure intact proteins after rapid online deglycosylation using PNGase Rc at low pH. Samples prepared immediately prior to mass spectrometry analysis using the automated sample-handling platform can reduce variability associated with autosampler residence time, as some proteins may undergo degradation or precipitation during storage in the autosampler.Although all glycoproteins in this study were effectively deglycosylated, the method’s efficiency depends on the characteristics of the individual glycoprotein. Therefore, optimizing method parameters─including the isocratic flow rate, glycoprotein incubation time with TCEP, and/or the addition of denaturing reagent─may improve the overall efficiency of the deglycosylation process.The PNGase Rc IMER stability over a series of injections was tested by using the trastuzumab antibody. The measurements were carried out with the enzyme column kept at the laboratory temperature. As shown in <a target="_blank" rel="noopener noreferrer" href="https://pubs.acs.org/doi/10.1021/acsomega.6c00577#fig5">Figure 5</a>, the results indicate that the column performance remained stable over the course of the 150 measurements, and no glycosylated form of the trastuzumab antibody heavy chain was detected. The activity of PNGase Rc in the presence of 5% acetonitrile and 5% propan-2-ol was evaluated using a bottom-up approach with human 2–1 haptoglobin, which was online-digested by a coimmobilized nepenthesin-2/pepsin IMER. In the absence of an organic solvent, the peptide IEKVVLHPNYSQVD remained fully deglycosylated throughout 30 injections. In contrast, in the presence of organic solvent, a marked loss of enzymatic activity was observed after only a few injections (<a target="_blank" rel="noopener noreferrer" href="https://pubs.acs.org/doi/suppl/10.1021/acsomega.6c00577/suppl_file/ao6c00577_si_001.pdf">Figure 2</a>).<img src="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/ACS_Omega_2026_11_17_25724_25729_Figure_5_Monitoring_the_stability_and_performance_of_PN_Gase_Rc_IMER_4a9b5a9c53.jpg" alt="ACS Omega 2026, 11, 17, 25724–25729: Figure 5. Monitoring the stability and performance of PNGase Rc IMER. Trastuzumab heavy chain was completely deglycosylated after 150 injections." srcset="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/thumbnail_ACS_Omega_2026_11_17_25724_25729_Figure_5_Monitoring_the_stability_and_performance_of_PN_Gase_Rc_IMER_4a9b5a9c53.jpg 170w," sizes="100vw" width="996" height="918"><h4>Conclusions</h4>Here, we demonstrate the potential of the PNGase Rc IMER for the online removal of N-glycans from intact monomeric glycoproteins reduced with TCEP. The column showed high sensitivity toward Hp, which has multiple glycosylation sites with various glycan structures, confirming its suitability for the profiling of complex glycoproteins. Bevacizumab and trastuzumab exhibited similar glycosylation profiles, with core-fucosylated biantennary glycans being the most abundant. Online deglycosylation with the PNGase Rc column resulted in a complete removal of the glycans from the heavy chains of both antibodies, proving that the column can be used for the rapid online deglycosylation of intact therapeutic mAbs. Moreover, the column remained stable over 150 measurements without any loss of activity, even when it was maintained at laboratory temperature. The significantly reduced reaction time, together with full automation and the absence of manual handling steps, substantially improves analytical throughput compared to conventional off-line deglycosylation workflows. These findings highlight the potential of the PNGase Rc IMER in the development of glycoprotein-based biopharmaceuticals, where detailed structural characterization of the protein part is critical for quality control, monitoring batch-to-batch variability, and stability testing.</div>

Online Deglycosylation of Monomeric Intact Proteins Using the PNGase Rc Immobilized-Enzyme Reactor

In the week of June 29, the following webinars await you in the field of liquid phase and especially HPLC and LC/MS.<blockquote><h4><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/webinars">👉 DETAILS AND REGISTRATION IN THE WEBINARS SECTION</a></h4>👉 Search and filter in the largest global database with over 5 500 GC, LC, MS and spectroscopy webinars.</blockquote><h5>1. Thermo Fisher Scientific: Insights from an IC specialist: To be suppressed or not suppressed?</h5><ul><li>Tu, 30.6.2026 09:00 CEST</li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/webinar/6310">Registration</a></li></ul>Join Thermo Fisher’s Ask the Experts session to learn how suppressor technology impacts ion chromatography performance, sensitivity, reliability, maintenance, and troubleshooting.<h5>2. SCIEX: Advancing Proteomics with ZenoTOF: From Single-Cell Analysis to Plasma Biomarker Discovery</h5><ul><li>Tu, 30.6.2026 11:30 CEST</li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/webinar/6311">Registration</a></li></ul>Discover how ZenoTOF high-resolution mass spectrometry is accelerating single-cell proteomics and plasma biomarker discovery through enhanced sensitivity, throughput, and automation.<h5>3. Agilent Technologies: Measuring Diverse Samples with UV/VIS Spectrometers and Integrating Spheres</h5><ul><li>Tu, 30.6.2026 20:30 CEST</li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/webinar/6052">Registration</a></li></ul>This webinar will discuss diffuse transmission and reflection UV/VIS measurements, including how to perform measurements with Agilent’s Cary 60 UV/VIS Spectrometer.<h5>4. Waters Corporation: Informatics series #33 Tips, Tricks and Best Practices</h5><ul><li>Th, 2.7.2026 11:00 CEST</li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/webinar/6315">Registration</a></li></ul>This interactive session revisits essential features, shortcuts, and practical techniques in Empower software that can streamline everyday laboratory work and reduce unnecessary effort.<h5>5. Waters Corporation: Unlocking Therapeutic Peptide Characterisation (GLP-1RAs) with Cyclic IMS</h5><ul><li>Th, 2.7.2026 15:00 CEST</li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/webinar/6313">Registration</a></li></ul>Discover how cyclic ion mobility spectrometry (cyclic IMS) improves characterization of GLP-1 analogues and therapeutic peptides, supporting development, quality control, and regulatory submissions.<h5>6. Agilent Technologies: Spectral Flow Cytometry Masterclass - Session 1</h5><ul><li>Fr, 3.7.2026 07:00 CEST</li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/webinar/6316">Registration</a></li></ul>Learn how full-spectrum flow cytometry enables high-dimensional cell analysis. Explore spectral flow technology, experimental design, and applications in immunology, oncology, and vaccine research.

Webinars LabRulezLCMS Week 27/2026

Article

Webinars

Video

Scientists

Environment

Water

Scientific article

Interview

Science and research

Everything from the world of analytical chemistry in one place. We connect people in solving their problems. At Labrulez you will find all the necessary information easily, quickly and clearly. Stop searching and start finding.

LabRulez

Organomation, founded in 1959, designs and manufactures high-quality nitrogen evaporators and extraction systems. Known for innovation and durability, their lab instruments are used globally for efficient sample preparation with strong customer support.

Organomation

Agilent Technologies

Shimadzu Corporation

SCIEX

Evosep Biosystems

Waters Corporation

Day two: Characterization and discovery<ul><li>Characterize and quantify calreticulin (CALR) arginylation using electron-activated top-down proteomics</li><li>Achieve in-depth profiling of metabolites and lipids in biological samples</li><li>Obtain accurate and reliable metabolite identification using electron-based fragmentation (EAD)</li><li>Detect trace amounts of pesticide residues in food by targeted and non-targeted, IDA and SWATH approaches</li><li>Enhance routine characterization of low-abundant sequence variant (SV) through fast and sensitive EAD-DDA</li></ul><h5>Agenda-at-a-glance</h5>Welcome and introduction to characterization and discoveryTop-down characterization of post-translational arginylation using electron activated dissociation (EAD)<ul><li>Learn about our top-down proteomics workflow for the characterization and quantification of calreticulin (CALR) arginylation. MS1 profile and MS2 fragmentation were characterized by EAD. Preferential fragmentation at the CALR N-terminals yielded sufficient c ions facilitating precise localization of the arginylation sites. Learn about:<ul><li>Arginylation regulates CALR degradation and ER function</li><li>EAD is efficient in characterizing N-terminal arginylation</li><li>The workflow sets up the foundation for unbiased top-down activity-based arginylation profiling</li></ul></li></ul>In-depth metabolomics and lipidomics analyses<ul><li>Routine measurement of metabolites and lipids has become a cornerstone of biomedical research. At the MPC, Helmholtz Munich, non-targeted analysis is based on the SCIEX ZenoTOF 7600 for accurate and in-depth analysis and annotation of metabolites and lipids from different biological specimens.<ul><li>Application of Zeno trap enabled non-targeted workflows to large scale metabolomics and lipidomics studies</li><li>Enhanced sensitivity enables deeper profiling of biological samples</li><li>Increased confidence in identifications through comprehensive structural elucidation using Electron activated dissociation (EAD)</li></ul></li></ul>MetID innovations in pharma: exploring new avenues for metabolite structure elucidationTime-of-flight mass spectrometry applications in food science: targeted and non-targeted approaches<ul><li>Time-of-flight mass spectrometry has become a key tool in analytical laboratories involved in food analyses. This instrumentation can be used for both targeted and non-targeted approaches. In this presentation, we will discuss:<ul><li>Overview of practical targeted and non-targeted approaches in food analysis</li><li>Application of a SWATH® approach to the analysis of pesticide residues in food</li><li>Application of IDA approaches in non-targeted food analyses</li></ul></li></ul>Reduce risk and accelerate cell line development with iCIEF-UV/MS technology<ul><li>Guide decisions during cell line development with the Intabio ZT system with more information on how process changes affect cell line and product stability. &nbsp;<ul><li>How to utilize icIEF-UV/MS to identify sequence variants</li><li>How this information can be used to create a mitigation strategy</li><li>What more information in less time means to groups throughout process development</li></ul></li></ul>Q&amp;A roundtable: A deeper look at high-resolution mass spectrometry<ul><li>Moderated by: ose Castro-Perez, Vice President of Product Management, SCIEX</li><li>Panelists include:<ul><li>Tom Lin, Instructor, Washington University in St. Louis</li><li>Michael Witting, Deputy Head Metabolomics and Proteomics Core and Executive Manager Metabolomics, Helmholtz Munich</li><li>Francisco José Díaz-Galiano, Postdoctoral researcher, University of Almería</li><li>Kirsten Nields, Principal Scientist, J&amp;J Innovative Medicines</li><li>Tatjana Talamantes, Senior Product Manager, Accurate Mass, SCIEX</li></ul></li></ul><blockquote>Moderator: Tatjana Talamantes, Senior Product Manager, Accurate Mass, SCIEXTatjana is a Senior Product Manager at SCIEX, overseeing accurate mass systems since 2021. She collaborates with R&amp;D, sales, and marketing teams to ensure effective project execution and portfolio management.Previously, Tatjana was a Product Manager at MOBILion Systems, leading the pre-commercialization of SLIM-based ion mobility instruments. She also has held roles at Thermo Fisher Scientific as a Sr. Vertical Marketing Specialist and Sr. Field Applications Scientist.Tatjana holds a B.A. in chemistry from Austin College and a Ph.D. in biomedical sciences and biochemistry from the University of North Texas Health Science Center.Jamie holds a B.Sc. in engineering physics from Queen’s University.Presenter: Tom Lin, Instructor, Washington University in St. LouisPresenter: Michael Witting, Deputy Head Metabolomics and Proteomics Core and Executive Manager Metabolomics, Helmholtz MunichPresenter: Francisco José Díaz-Galiano, Postdoctoral researcher, University of AlmeríaPresenter: Kirsten Nields, Principal Scientist, J&amp;J Innovative MedicinesPresenter: Tatjana Talamantes, Senior Product Manager, Accurate Mass, SCIEX</blockquote>

SCIEX summit Day two: Characterization and discovery

Importance of LC-MS in food and environmental testing, pharmaceutical and biopharmaceutical discovery and development and biomedical and omics research.

CIEX summit Day two: Characterization and discovery

Day three: Quantitation and screening<ul><li>Enhanced sensitivity and robustness deliver stringent quantitation for veterinary drug testing for meat</li><li>See how intuitive, compliant-ready SCIEX OS software enables pharmacokinetic parameter monitoring with ease and reliability</li><li>Understand the challenges and best practices for oligoneucleotide analysis by LC-MS&nbsp;</li><li>Discover how exploiting fast acquisition rates can be used to identify and quantify over 2250 fatty-acids lipids</li><li>Hear about the accurate detection and quantitation of trace-lelvel PFAS compounds</li></ul><h5>Agenda-at-a-glance</h5>Welcome and introduction to quantitation and screening&nbsp;&nbsp;&nbsp;&nbsp;Veterinary drug analysis: SCIEX 7500 system vs 7500+ system<ul><li>Biochemie Lab shares their expertise in veterinary drug analysis. With over 25 years of experience and strict adherence to Commission Regulation (EU) No 37/2010, Biochemie Lab processes more than 100,000 samples annually, providing comprehensive food and environmental testing.<ul><li>Learn how Biochemie Lab conducts veterinary drug testing with specialized veterinarians, covering a wide range of analyses, including residual veterinary drugs, anabolic substances, and microbiological tests.&nbsp;</li><li>Discover how they overcome challenges in analyzing complex animal-origin matrices like meat and offal using the SCIEX QTRAP 7500 system.</li><li>Explore their proficiency testing, method validation results, and ask questions directly from leading experts in the field.</li></ul></li></ul>Maximizing analytical potential and navigating changes in the validated laboratory with SCIEX OS software<ul><li>Having the right information available at every stage of the process is vital to bringing safe and effective therapies to market.. SCIEX OS software is a vital component of this process, from discovery to development. See how:<ul><li>Your pharma lab workflows can benefit from SCIEX OS software</li><li>Central Admin Console enables comprehensive audit configurations for full traceability</li><li>Professional services are available to assist in migrating from legacy Analyst software and change control support plansis</li></ul></li></ul>Approaches for the bioanalytical analysis of oligonucleotide therapies<ul><li>Oligonucleotide therapeutics are on the rise in drug development and regulatory submissions. These drugs face challenges with bioanalytical extraction and analytical detection due to their chemical backbone or other stability-enhancing modifications.<ul><li>Learn about bioanalytical challenges and best practices for oligonucleotide analysis</li><li>Hear case studies in the quantitation of oligonucleotide therapies using different mass spectrometry platforms</li><li>Gain insights into improved method development for obtaining validated assays for regulatory evaluations using high-resolution mass spectrometry in early-stage development</li></ul></li></ul>Fast scanning quantitative lipidomics analysis using the SCIEX 7500+ system<ul><li>A panel of &gt;2250 lipids was used to demonstrate the power and capability of the SCIEX 7500+ system to sensitively identify and quantify lipids at the fatty acid level using a multiple reaction monitoring (MRM). HILIC-like chromatography provides class separation to mitigate inter-lipid class isobaric overlap, but means that the speed at which individual MRM transitions are measured is crucial to ensure good coverage and quantitative accuracy.<ul><li>The ~4X faster analytical speed of the SCIEX 7500+ system improves the quantitative performance of a large, broadly targeted lipid panel</li><li>The number of lipid molecular species quantified with %CV &lt; 20 increased 59% during a period of the highest</li><li>MRM concurrency (n = 925) compared to the fastest speed recommended on the SCIEX 7500 system The faster MRM acquisition rates improve peak shapes by increasing the number of data points across the peak and providing better resolution of near-eluting lipid isomers</li></ul></li></ul>From sample collection to data processing - PFAS program at State Hygienic Lab<ul><li>The State Hygienic Lab at University of Iowa had the PFAS program running for couple of years and is accredited and certified by the state, EPA, and UCMR5 program to test for PFAS in water samples. However, testing encompasses different environmental and biological matrices. This presentation will look at the program and focus on:<ul><li>Approaches from sample collection to data processing and reporting.</li><li>Testing for PFAS in water matrices (drinking, raw, well, surface, and groundwater) based on EPA 537.1 and 533 FAS methods.</li><li>New method for PFAS in biological samples.</li></ul></li></ul>Q&amp;A roundtable: &nbsp;quantitation and screening<ul><li>Moderated by: Ian Moore, Sr. Technical Product Manager, Nominal Mass, SCIEX</li><li>Panelists include:<ul><li>Roberto Riccio, Biochemie Lab</li><li>Shane Karnik, Senior Laboratory Director, Aliri Bioanalysis</li><li>Ebru Selen, Biologics Applications Scientist, SCIEX</li><li>Paul Baker, Senior Scientific Liason, Lipidomics and Metabolomics, SCIEX</li><li>Craig Butt, Senior Manager, Scientific Marketing, Applied Markets, SCIEX</li></ul></li></ul><blockquote>Moderator: Ian Moore, Sr. Technical Product Manager, Nominal Mass, SCIEXWith over ten years in product development, Ian is the Senior Technical Product Manager for nominal mass LC-MS/MS systems at SCIEX. He has also served as a Technical Product Manager and Global Technical Marketing Manager. Ian began his SCIEX career as an Application Scientist, focusing on biologics bioanalysis and DiscoveryQuant software validation.Before SCIEX, Ian was the Lead Analytical Scientist at Custom Biologics, overseeing LC-MS/MS method development and clinical trial analysis. He also served as a Senior Scientist at Affinium Pharmaceuticals, focusing on metabolic stability profiling and enzyme inhibition assays.Ian holds a postdoctoral position at McMaster University, specializing in antibiotic resistance and enzyme inhibitor screeningPresenter: Roberto Riccio (Biochemie Lab)Presenter: Shane Karnik (Senior Laboratory Director, Aliri Bioanalysis)Presenter: Ebru Selen (Biologics Applications Scientist, SCIEX)Presenter: Paul Baker (Senior Scientific Liason, Lipidomics and Metabolomics, SCIEX)Presenter: Craig Butt (Senior Manager, Scientific Marketing, Applied Markets, SCIEX)</blockquote>

SCIEX summit Day three: Quantitation and screening

<h4>The Waters 2024 Virtual Summer School - An Educational Journey to Master Food &amp; Environmental Analysis</h4>Unlock the full potential of LC-MS techniques with our immersive and educational sessions at the Waters Virtual F&amp;E Late Summer School 2024. From September 24th to 26th, engage with leading experts and discover cutting-edge methods for environmental and food analysis.<h5>Why attend?</h5><ul><li>Comprehensive Learning: Dive deep into advanced LC-MS techniques and gain practical knowledge to enhance your laboratory's analytical capabilities.</li><li>Expert Insights: Learn from industry leaders and gain firsthand experience through detailed modules on chromatography, mass spectrometry, and sample preparation.</li><li>Regulatory Compliance: Stay ahead with the latest insights on EU regulations for PFAS analysis in food and water, ensuring your lab meets stringent standards.</li></ul><h3>Episode #7: Quantification for Targeted Analysis | F&amp;E Summer School - Day 2 - Module 3</h3>MS Quan is an application in the waters_connect™ for Quantitation software platform that is designed to streamline the LC-MS/MS data processing and review with innovative workflows, data visualization and data navigation. The MS Quan application’s main workflows and overarching features such as task-oriented workflow, batch-level review, and exception-focused review are introduced and illustrated with a PFAS analysis dataset.<h5>What you'll learn:</h5><ul><li>How to create processing method</li><li>Data review with exception focus review</li><li>Compare data and evaluate peak integration</li><li>Export and report of final results</li></ul><blockquote>Presenter:&nbsp;Helge Grunwald (Sr Sales Applications Chemist, Waters Corporation)Helge is part of the Customer Success team at Waters with a focus on LC-MS/MS application and sales support. He works in this role for more than 4 years and gained experience in previous roles as project manager at Intertek and method developer at Basilea Pharmaceutica after he finished his Master of Science in Life Science at FH Nordwestschweiz.</blockquote>

Waters Corporation: The Waters 2024 Virtual Summer School

Quantification for Targeted Analysis

The MS Quan application’s main workflows and overarching features are introduced and illustrated with a PFAS analysis dataset. 

<h4>The Waters 2024 Virtual Summer School - An Educational Journey to Master Food &amp; Environmental Analysis</h4>Unlock the full potential of LC-MS techniques with our immersive and educational sessions at the Waters Virtual F&amp;E Late Summer School 2024. From September 24th to 26th, engage with leading experts and discover cutting-edge methods for environmental and food analysis.<h5>Why attend?</h5><ul><li>Comprehensive Learning: Dive deep into advanced LC-MS techniques and gain practical knowledge to enhance your laboratory's analytical capabilities.</li><li>Expert Insights: Learn from industry leaders and gain firsthand experience through detailed modules on chromatography, mass spectrometry, and sample preparation.</li><li>Regulatory Compliance: Stay ahead with the latest insights on EU regulations for PFAS analysis in food and water, ensuring your lab meets stringent standards.</li></ul><h3>Episode #9: PFAS in Food | F&amp;E Summer School - Day 3 - Module 1</h3>The European Commision published for the first time maximum levels for the so-called “EU 4” PFAS (PFHxS, PFOS, PFOA and PFNA) in eggs, meat and fish with Regulation EU 2023/915. This was an expected result of EFSA’s letter of concern on those 4 PFAS and labs reacted accordingly. A more challenging task came with the EURL PFAS Guidance Document and a bit later with the Recommendation EU 2022/1431. The target LOQs for the EU 4 PFAS were set at 0.001 µg/kg in fruits, vegetables and babyfood. We will discuss the successful method implementation from sample preparation to final report and hear real-life experiences from our guest speaker Victoria Erdely (Eurofins GfA) and Katharina Rund (EURL PFAS).<h5>What you'll learn:</h5><ul><li>How to reach lowest levels of PFAS in food and work according to Recommendation EU 2022/1431 using Xevo TQ Absolute in combination with UniSpray ion source</li><li>How LC method development on Premier LC gives you the widest PFAS panel and separates interferences.</li><li>Tips &amp; tricks from the demo lab to avoid PFAS contamination, implement new analytes, speed up data processing, and keep best performance of your system</li><li>About a special PFAS training to help you implement the method in the lab.</li></ul><blockquote>Presenter:&nbsp;Dr. Sara Stead (Consulting Scientist, Food and Environmental, Scientific Operations, Waters Corporation)In her current position, Sara is a Principal Sales Application Chemist specializing in food and environmental LC-MS/MS based applications within the Waters UK and Ireland demo laboratory. Sara has worked in F&amp;E analysis with various research interests including the development of both multi-residue HRMS screening and targeted LC/GC MS based methods for the past 25 years in both the government and private sectors. ​Prior to joining Waters Sara was employed as a Lead Scientist at the Food and Environment Research Agency (FERA, Defra, UK) for 14 years. Sara has participated in EU Food and Veterinary Office (FVO) audit inspections, was an expert on behalf of the International Atomic Energy Agency (IAEA) and a member of the EuroResidue conference scientific committee.Presenter:&nbsp;Dr. Stuart Adams (Principal Scientist, Market Development, Food and Environmental Applications, Europe, Waters Corporation)Stuart has been developing methods for the determination of contaminants in food and the environment for over 17 years and has been with Waters Corporation since 2018. Stuart's previous role was as a senior analytical chemist at Fera (the UK’s National Reference Laboratory) and moved to Waters to focus on application development in the European region. He now serves as the attached scientist to the European Market Development team responsible for the food and environmental application areas. In his role, he works with customers to understand their analytical challenges and helps address them with Waters technologies.Presenter:&nbsp;Victoria Erdely (Head of Department - Method and Instrument Support, Eurofins GfA)Presenter:&nbsp;Dr. Katharina Rund (Food Chemist, EU Reference Laboratory for halogenated POPs in Feed and Food)</blockquote>

PFAS in Food

We will discuss the successful method implementation from sample preparation to final report and hear real-life experiences.

<h4>The Waters 2024 Virtual Summer School - An Educational Journey to Master Food &amp; Environmental Analysis</h4>Unlock the full potential of LC-MS techniques with our immersive and educational sessions at the Waters Virtual F&amp;E Late Summer School 2024. From September 24th to 26th, engage with leading experts and discover cutting-edge methods for environmental and food analysis.<h5>Why attend?</h5><ul><li>Comprehensive Learning: Dive deep into advanced LC-MS techniques and gain practical knowledge to enhance your laboratory's analytical capabilities.</li><li>Expert Insights: Learn from industry leaders and gain firsthand experience through detailed modules on chromatography, mass spectrometry, and sample preparation.</li><li>Regulatory Compliance: Stay ahead with the latest insights on EU regulations for PFAS analysis in food and water, ensuring your lab meets stringent standards.</li></ul><h3>Episode #10: PFAS Analysis in Drinking, Ground, and Surface Water | F&amp;E Summer School - Day 3 - Module 2</h3>Analysis of PFAS is an essential part of water testing programs and becoming a regular requirement for monitoring in environment and food sources. As regulations, like the EU Drinking Water Directive, the EU Groundwater Directive, and the EU Water Framework Directive, have been updated or are in the process for an update, the requirements for method sensitivity have become more demanding. Whilst concentration levels go down, direct injection methods are increasingly desirable to laboratories carrying out routine analysis of PFAS where analyte preconcentration is not deemed necessary or required. They have a simple sample preparation method, which not only reduces the opportunity for contamination and error but speeds up analysis time and the requirements for large volumes of samples. This can provide labs with a higher throughput of samples and lower analysis costs.Dorrit Griesshaber from the Office for Environment and Energy in Basel (SZ) and Jenny Davies from Element Materials Technology in Flinshire (UK) will give insights how the analysis of PFAS in environmental samples works in routine testing labs.<h5>What you'll learn:</h5><ul><li>How to reach lowest levels of PFAS and work according to EU regulation using Xevo TQ Absolute in combination with UniSpray ion source,</li><li>LC method development on Premier LC and system modification for direct injection with large volume,</li><li>Tips &amp; tricks from the demo lab to avoid PFAS contamination, implement new analytes, speed up data processing, and keep best performance and</li><li>A special PFAS training to help you implement the method in the lab.</li></ul><blockquote>Presenter:&nbsp;Dr. Sara Stead (Consulting Scientist, Food and Environmental, Scientific Operations, Waters Corporation)Presenter:&nbsp;Aron Dekkers (Sales Application Chemist, Waters Corporation)Aron is part of the Customer Success team at Waters BeNeLux with a focus on Food &amp; Environmental LC-MS/MS applications and sales support. His special interest areas are PFAs and pesticides. He works in this role for more than 4 years. Aron finished his B.S. in Chemistry at Fontys Eindhoven (NL).Presenter:&nbsp;Dorrit Griesshaber (Amt für Umwelt und Energy (AUE))Presenter:&nbsp;Jenny Davies (Technical Director, Element Materials Technology)</blockquote>

PFAS Analysis in Drinking, Ground, and Surface Water

We will give insights how the analysis of PFAS in environmental samples works in routine testing labs. 

In this session, we explore how cutting-edge technology can detect the early signs of infectious disease with precision and speed. Early identification of disease markers can significantly enhance patient care by allowing for faster, more effective treatments.Learn how Evosep One’s robustness, sensitivity, and efficiency are helping laboratories and clinicians stay ahead of disease progression, providing key insights that lead to better health outcomes.Accurate and early detection of mycobacterial pathogens is critical for improving patient outcomes. We developed and validated multiple novel diagnostic methods. First, an immuno-affinity liquid chromatography–tandem mass spectrometry (ILM) assay that quantifies Mycobacterium tuberculosis CFP10 peptides and HIV-1 p24 in serum, showing high sensitivity and specificity in both adults and children. This method allows early detection of HIV and TB and monitors treatment responses effectively. The second approach involves an automated peptidomics pipeline that rapidly identifies mycobacterial species and subspecies from early growth cultures, including drug-resistant strains, significantly reducing diagnosis time compared to current clinical practices. These methods present significant advancements for managing the mycobacterial diseases.<blockquote>Presenter: PhD. Tony Hu (Center for Cellular &amp; Molecular Diagnostics, Tulane Cancer Center Translational Oncology Research Program Leader)Presenter:&nbsp;Aaron Scott (Infection Medicine (BMC) – Faculty of Medicine, Lund University)</blockquote>

Evosep: Tracking early signs of infectious disease with Evosep One to improve patient outcomes

Tracking early signs of infectious disease with Evosep One to improve patient outcomes

Learn how Evosep One’s robustness, sensitivity, and efficiency are helping laboratories and clinicians stay ahead of disease progression.

Tracking early signs of infectious disease with Evosep One

This webinar will guide you through optimizing your Q-TOF for superior data quality by selecting the most suitable tune mode for your samples.You will learn about the different optimisation workflows available within MassHunter Acquisition, including how to optimise Multiple Reaction Monitoring (MRM) methods for new compounds. We will also review key tools for creating and editing worklists, and discuss the benefits of Intelligent Reflex tools, demonstrating how they can be effectively implemented in your workflows.This webinar is designed to enhance your understanding and application of MassHunter Acquisition, ensuring you can achieve optimal performance in your analytical processes.<blockquote>Presenter: Day Powell (Field Application Specialist, Agilent Technologies)Day has worked for Agilent as an Environmental Application Specialist for over a year, before this he worked for United Utilities (UU) as a Technical Specialist responsible for developing new methodologies for both LC/MS and GC/MS applications. Day has worked with PFAS for several years and helped UU to UKAS accredit a novel method for 47 PFAS in drinking water using direct injection to address the latest DWI regulations. Presenter: Jonathan Spencer (Application Specialist, Agilent Technologies)Jonathan studied BSc Natural Sciences at the University of Nottingham and later went on to Sheffield Hallam University to study a MSc in Forensic Science.Following graduation, he spent 2 years as a Confirmatory Analyst in an anti-doping and forensic toxicology lab, before joining Agilent as an LC/MS Applications Scientist. At Agilent, he focuses on small molecule applications using LC/TQ and LC/Q-TOF in fields of like food, forensic and environmental analysis.</blockquote>

Agilent Technologies: MassHunter Masterclass Months

MassHunter Acquisition for LC/TQ and MRM Method Optimisation

This session will provide a comprehensive overview of the various aspects of MassHunter Acquisition for Liquid Chromatography/Triple Quadrupole (LC/TQ) systems.

Measurement of FT4 and FT3 is typically performed by immunoassay, however these can be prone to suffer from interferences and a lack of selectivity. Currently, the accepted gold standard for the measurement of FT4 and FT3 is using equilibrium dialysis (ED) and combined with the use of LC-MS/MS can overcome the issues with immunoassay in the measurement of FT4 and FT3. However, the equilibrium dialysis procedure can be quite time consuming and often being performed overnight.Here, we describe a simple clinical research method to perform ED using a commercially available device followed by sample preparation by solid phase extraction (SPE) and UPLC-MS/MS analysis using the Waters™ ACQUITY™ UPLC and analytically sensitive Xevo™ TQ Absolute Mass Spectrometer for clinical research. Data analysis and review has been simplified with the use of the waters_connect™ with QUAN Review Software. This has allowed for the complete workflow including equilibrium dialysis to be performed within a typical working day.Simplified Equilibrium Dialysis for the UPLC-MS/MS Analysis of Free Testosterone (FT) for Clinical ResearchHistorically, the measurement of free testosterone in human serum has presented a challenge for laboratory scientists, with such a large portion bound and the complexity and time involved in “gold standard” equilibrium dialysis. With a simple, fast, workflow combined with the analytical sensitivity afforded by the Waters Xevo™ TQ Absolute Mass Spectrometer, a newly developed, precise, accurate and selective clinical research method will be presented.<blockquote>Presenter: Robert Wardle (Senior Clinical Scientist, Waters Corporation)Robert Wardle is currently a Senior Scientist employed at Waters Corporation in Wilmslow, UK, performing research and development of applications and products for Clinical Research. His primary area of research is vitamins and in particular vitamin D metabolites, steroid hormones and in-depth knowledge of offline and online automation.Robert joined Waters in 2010 as a Clinical Validation Scientist, playing a key role in verification activities for the MassTrak XE Immunosuppressants kit available in the EU. He moved into his current role as a Senior Scientist in 2013, where he developed clinical research methods for a range of applications including vitamin D metabolites, estrogens, a large panel of steroid hormones and more recently this application on free T4 and free T3.Presenter: Stephen Balloch (Senior Clinical Scientist, Waters Corporation)Stephen Balloch graduated from the University of York (UK) with a Master’s degree in Chemistry, which included a strong focus on analytical chemistry. Subsequently he worked as a laboratory scientist in a GLP compliant research facility, progressing to Study Director. And, since 2010, he has been part of the clinical team at Waters (Wilmslow, UK). His principal focus has been on the development and validation of bioanalytical methods according to CLSI guidelines, with a focus on therapeutic drug monitoring. Additionally, he has supported newborn screening, vitamin and steroid analysis, including this clinical research method for free testosterone</blockquote>

Free Testosterone and Free T3/T4

Simplified Equilibrium Dialysis and SPE Method for the UPLC™-MS/MS Analysis of Free Thyroxine (FT4) and Triiodothyronine (FT3) for Clinical Research.

Join us for an enlightening Digital Classrooms session focused on the pivotal advancements in mass spectrometry (MS) technology and its applications in personalized health monitoring, early disease detection, and critical care management.This session, led by esteemed experts Dr. Naatasha Isahak and Dr. Abhik Banerjee, Zonal Technical Chief of Apollo Diagnostics' East Zone, will uncover how MS is transforming modern healthcare.Explore how MS technology facilitates the quantification of vitamins, hormones, metabolites, and proteins, providing insights into metabolic health, nutritional status, and organ function. Additionally, through real-world case studies, learn how MS is utilized for rapid diagnosis and therapeutic monitoring in acute conditions, such as sepsis and organ failure.Don’t miss this opportunity to understand the technical aspects of MS-based assays, as well as practical considerations for integrating these tools into clinical workflows for enhanced patient outcomes. Whether you are involved in clinical diagnostics or health management, join us to discover the expanding influence of mass spectrometry in today’s healthcare landscape.<h5>Learning Objectives:</h5><ul><li>Delve into the latest advancements in MS technology and its applications in personalized health monitoring, early disease detection, and critical care management.</li><li>Discover how MS quantifies biomarkers like vitamins, hormones, metabolites, and proteins, and its role in assessing metabolic health, nutritional status, and organ function.</li><li>Gain practical insights into seamlessly integrating MS-based assays into clinical workflows, with real-world case studies demonstrating its effectiveness in rapid diagnosis and therapeutic monitoring of acute conditions like sepsis and organ failure.</li><li>Explore a concise overview of Shimadzu's innovative solutions tailored for wellness diagnostics and critical care applications.</li></ul><blockquote>Presenter: Dr. Abhik Banerjee (Zonal Technical Chief, East Zone, Apollo Diagnostics)Dr. Abhik Banerjee is a highly accomplished pathologist with over 11 years of post-MD pathology experience and more than a decade as a Consultant Pathologist. He currently serves as the Zonal Technical Chief for East Zone at Apollo Diagnostics, overseeing the operations of around 30 laboratories in East India. A specialist in laboratory medicine, pathology, and quality control, Dr. Banerjee has spearheaded the establishment of the first LC-MS/MS (Tandem mass spectrometry) setup in Eastern India at Suraksha Diagnostics, Kolkata. He has held leadership roles such as Lab Director and Chief of Quality at Suraksha Diagnostics' COVID-19 Cell, and was the Nodal Officer for the only CAP-accredited medical laboratory in East India. He has contributed to the field with publications in national journals and received the Dx Leadership Award in 2019. Additionally, Dr. Banerjee is a certified lead assessor for CAP audits, has extensive experience with NABL and ISO 15189 audits, and has been an active speaker and reviewer for medical journals.Presenter: Naatasha Isahak (Market Specialist (Clinical and Forensics), Shimadzu (Asia Pacific) Pte Ltd)Naatasha Isahak is a Product Specialist for MALDI and Life Sciences Products from Shimadzu Asia Pacific Pte Ltd. She has received her PhD from the University of Sydney (Chemistry) working on surface initiated polymerisation on silica nanoparticles using RAFT polymerisation and bioorthogonal conjugation of peptides using Native Chemical Ligation. She then spent 5 years working on developing platforms for stem cells and organoids characterization that included working with microfluidic devices and helical polymers. Naatasha joined Shimadzu in 2022 to expand her experiences to MALDI characterization on materials and biological samples.</blockquote>

Shimadzu: Wellness Diagnostics And Critical Care

Wellness Diagnostics And Critical Care

We will uncover how MS is transforming modern healthcare.

In this webinar, Dr Stuart Best, Deputy Director, Drug Metabolism and Pharmacokinetics (DMPK), Sygnature Ltd, will provide an overview of analytical approaches in Discovery Bioanalysis CNS measurement, to deliver more information from lower sample volume and align with the 3R principles.Drug discovery programs that target the Central Nervous System require bioanalytical measurement of test compounds and neurotransmitter concentrations to establish a pharmacokinetic-pharmacodynamic (PK-PD) relationship. Bioanalytical assessment of unbound compounds in blood, brain tissue, and cerebrospinal fluid describes its distribution for the systemic circulation into the CNS. The inherently high sensitivity and specificity of LC-Triple Quadrupole Mass Spectrometry enables low level detection in small sample volumes, allowing serial sampling from single animals, reducing animal use and inter-animal variability, supporting the 3Rs principles (replacement, reduction, refinement)The bioanalysis of neurotransmitters such acetylcholine and monoamines, is challenging due to low molecular weight, high polarity, instability, and low endogenous concentrations. At Sygnature, the in vivo Pharmacology team employ microdialysis to permit assessment of neurotransmitter changes in specific brain regions. The low endogenous concentrations in brain regions and collection through dialysis probe into artificial CSF lowers further quantitation limits for neurotransmitter detection and lead to the requirements for highly sensitive and specific analytical approaches.This presentation will describe the above approached to CNS measurement and how LC-Triple Quadrupole Mass Spectrometry enables Sygnature scientists to align to the 3R principles and maximize data output from small samples and relate test compound concentrations to neurotransmitter changes. Truly, achieving on the concept of ‘More from Less’ Stuart will also present further refinement models for assessing test compound impact on acetylcholine and enabling more physiologically relevant measurements.<h4>Key Learning Objectives:</h4><ul><li>Understand the challenges as CNS measurements of test compounds and neurotransmitter concentrations to establish PK-PD relationships</li><li>Explore the complexities of neurotransmitter bioanalysis in discovery DMPK due to low concentrations and instability</li><li>Learn the roles of LC-Triple Quadrupole Mass Spectrometry enabling sensitive detection in small samples and alignment to the 3Rs (replacement, reduction, refinement) principles</li></ul><div><blockquote>Presenter: Dr Stuart Best (Deputy Director, DMPK, Sygnature Ltd)Dr Best's expertise spans regulated and discovery bioanalysis and discovery DMPK, from supporting DMPK screening (solubility, log D, metabolic stability, permeability, plasma protein binding, etc) through in vivo assessment of compounds to more detailed profiling to support candidate nomination and human dose prediction, including the assessment of potential risk from drug-drug interactions.During his time in the industry Dr Best has expanded the utilisation of mass spectrometry (specifically triple quadrupole LC-MS/MS) to help solve drug discovery project challenges with a strong focus on maximizing data capture from in vivo samples, refining experimental designs to permit better PD endpoints and expanding LC-MS/MS support for biological screening assays, where a mass spectrometry end-point is required, for the measurement of more challenging endogenous analytes.</blockquote></div>

More from less: LC-MS/MS an Enabling Technology to Maximize Bioanalytical Data Collection from Small Sample Volumes

An overview of analytical approaches in Discovery Bioanalysis CNS measurement, to deliver more information from lower sample volume.

LCMS webinars focusing on LC/QQQ - page 15